APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucagon-like Peptide-2 (GLP-2) Agonist

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Growth and Trends Forecast to 2032

2 January 202670 pages

Choose your research edition.

Industry ResearchGlucagon-like Peptide-2 (GLP-2) Agonist Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Glucagon-like Peptide-2 (GLP-2) Agonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist include Takeda Pharmaceuticals. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Glucagon-like Peptide-2 (GLP-2) Agonist market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Glucagon-like Peptide-2 (GLP-2) Agonist market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Glucagon-like Peptide-2 (GLP-2) Agonist market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Glucagon-like Peptide-2 (GLP-2) Agonist.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Glucagon-like Peptide-2 (GLP-2) Agonist market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Glucagon-like Peptide-2 (GLP-2) Agonist Market by Company

Takeda Pharmaceuticals

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type

Gattex

Revestive

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application

Hospital

Pharmacy

Other

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon-like Peptide-2 (GLP-2) Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon-like Peptide-2 (GLP-2) Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon-like Peptide-2 (GLP-2) Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Glucagon-like Peptide-2 (GLP-2) Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Gattex Table 2. Major Company of Revestive Table 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type (2021-2026) Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (US$ Million) Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type (2021-2026) Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2026) & (US$/Unit) Table 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type (2027-2032) Table 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (US$ Million) Table 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type (2027-2032) Table 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2027-2032) & (US$/Unit) Table 14. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 15. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 17. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 21. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (US$ Million) Table 24. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends Table 25. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers Table 26. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges Table 27. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Company (2021-2026) Table 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Company (2021-2026) & (K Units) Table 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Company (2021-2026) Table 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Glucagon-like Peptide-2 (GLP-2) Agonist Major Company Production Sites and Headquarters Table 35. Global Glucagon-like Peptide-2 (GLP-2) Agonist Company, Product Type & Application Table 36. Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Glucagon-like Peptide-2 (GLP-2) Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2026) & (K Units) Table 41. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Region (2021-2026) Table 42. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2026) & (US$ Million) Table 43. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Region (2021-2026) Table 44. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2027-2032) & (K Units) Table 46. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Region (2027-2032) Table 47. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2027-2032) & (US$ Million) Table 48. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Region (2027-2032) Table 49. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 52. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application (2021-2026) Table 53. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (US$ Million) Table 54. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application (2021-2026) Table 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2026) & (US$/Unit) Table 56. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 57. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application (2027-2032) Table 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (US$ Million) Table 59. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application (2027-2032) Table 60. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2027-2032) & (US$/Unit) Table 61. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 62. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 64. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 68. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (US$ Million) Table 71. Takeda Pharmaceuticals Company Information Table 72. Takeda Pharmaceuticals Business Overview Table 73. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio Table 75. Takeda Pharmaceuticals Recent Development Table 76. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 77. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 78. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2026) Table 79. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 80. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Country (2027-2032) Table 81. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 82. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026) & (US$ Million) Table 83. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country (2021-2026) Table 84. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 85. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Share Forecast by Country (2027-2032) Table 86. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 87. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 88. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2026) Table 89. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 90. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Country (2027-2032) Table 91. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 92. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026) & (US$ Million) Table 93. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country (2021-2026) Table 94. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 95. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Share Forecast by Country (2027-2032) Table 96. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 97. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 98. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2026) Table 99. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 100. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Country (2027-2032) Table 101. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 102. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026) & (US$ Million) Table 103. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country (2021-2026) Table 104. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 105. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Share Forecast by Country (2027-2032) Table 106. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 107. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 108. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2026) Table 109. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 110. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Country (2027-2032) Table 111. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026) & (US$ Million) Table 113. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country (2021-2026) Table 114. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Share Forecast by Country (2027-2032) Table 116. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 118. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2026) Table 119. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Country (2027-2032) Table 121. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026) & (US$ Million) Table 123. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country (2021-2026) Table 124. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Share Forecast by Country (2027-2032) Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List Table 129. Glucagon-like Peptide-2 (GLP-2) Agonist Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Glucagon-like Peptide-2 (GLP-2) Agonist Image Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (2021-2032) & (US$ Million) Figure 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2021-2032) & (K Units) Figure 5. Gattex Image Figure 6. Global Gattex Sales YoY Growth (2021-2032) & (K Units) Figure 7. Revestive Image Figure 8. Global Revestive Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Type 2025 VS 2032 Figure 11. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type in 2025 Figure 12. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type in 2025 Figure 13. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type in 2025 Figure 14. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type in 2025 Figure 17. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Glucagon-like Peptide-2 (GLP-2) Agonist Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Pharmacy Image Figure 26. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Application 2025 VS 2032 Figure 31. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application in 2025 Figure 32. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application in 2025 Figure 33. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application in 2025 Figure 34. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application in 2025 Figure 37. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application in 2025 Figure 41. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Gattex
  • Revestive
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Type
  6. 1.3.1 Gattex
  7. 1.3.2 Revestive
  8. 1.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Type
  9. 1.4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
  2. 2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers
  3. 2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges
  4. 2.4 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2026)
  2. 3.2 Global Top Players by Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2021-2026)
  3. 3.3 Global Top Players by Glucagon-like Peptide-2 (GLP-2) Agonist Price (2021-2026)
  4. 3.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Major Company Production Sites & Headquarters
  6. 3.6 Global Glucagon-like Peptide-2 (GLP-2) Agonist Company, Product Type & Application
  7. 3.7 Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Glucagon-like Peptide-2 (GLP-2) Agonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Glucagon-like Peptide-2 (GLP-2) Agonist Tier 1, Tier 2, and Tier 3
4 Glucagon-like Peptide-2 (GLP-2) Agonist Regional Status and Outlook
  1. 4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Historic Market Size by Region
  3. 4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecasted Market Size by Region
  7. 4.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Glucagon-like Peptide-2 (GLP-2) Agonist by Application
  1. 5.1 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Application
  6. 5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda Pharmaceuticals
  2. 6.1.1 Takeda Pharmaceuticals Company Information
  3. 6.1.2 Takeda Pharmaceuticals Business Overview
  4. 6.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio
  6. 6.1.5 Takeda Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country
  2. 7.1.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026)
  4. 7.1.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032)
  5. 7.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  6. 7.2.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026)
  8. 7.2.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country
  2. 8.1.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026)
  4. 8.1.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  6. 8.2.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026)
  8. 8.2.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country
  2. 9.1.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  6. 9.2.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country
  2. 10.1.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026)
  4. 10.1.3 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032)
  5. 10.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  6. 10.2.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026)
  8. 10.2.3 South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country
  2. 11.1.1 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  6. 11.2.1 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Analysis
  2. 12.1.1 Glucagon-like Peptide-2 (GLP-2) Agonist Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process
  7. 12.2 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
  10. 12.2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst